Stay updated with breaking news from Practice Patterns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- ASCENTTM, a Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada...
Vifor Pharma Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus Monday, March 8, 2021 1:10PM IST (7:40AM GMT) St. Gallen, Switzerland & Stamford, Conn., United States: FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients Regulatory News: Vifor Pharma and Cara T...
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA* injection in hemodialysis patients with moderate-to-severe pruritus If approved, KORSUVA injection would be first therapy for treatment of pruritus in hemodialysis patients Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210307005039/en/ Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for ... Cara Therapeutics, Inc.March 8, 2021 GMT FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients STAMFORD, Conn, and ST. GALLEN, Switzerland, March 08, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics (Nasdaq:CARA) and Vifor Pharma today announced that the U.S. Food a...
TMCnet News Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus [December 28, 2020] Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus First NDA submission for Companyâs lead program, KORSUVA⢠Injection â NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection â STAMFORD, Conn., Dec. 28, 20...